Are there any drug‑drug interactions between Xarelto (rivaroxaban), acyclovir, and hydroxyurea?

No Clinically Significant Drug-Drug Interactions Between Xarelto (Rivaroxaban), Acyclovir, and Hydroxyurea

Based on available evidence, there are no documented clinically significant drug-drug interactions between rivaroxaban (Xarelto), acyclovir, and hydroxyurea that would require dose adjustment or avoidance of this combination. However, close monitoring for bleeding is warranted given hydroxyurea's hematologic effects.

Rivaroxaban Interaction Profile

Rivaroxaban's drug interactions are well-characterized and primarily involve:

• Strong dual CYP3A4 and P-glycoprotein (P-gp) inhibitors or inducers (e.g., ketoconazole, ritonavir, rifampin) which should be avoided 1
• Moderate CYP3A4/P-gp inhibitors are generally safe with normal renal function but require caution in renal impairment 1

Analysis of Each Drug

Acyclovir with Rivaroxaban

• No documented interaction exists between acyclovir and rivaroxaban
• Acyclovir is not a CYP3A4 or P-gp inhibitor/inducer
• Acyclovir is primarily renally eliminated unchanged
• One study showed hydroxyurea can enhance acyclovir activity against resistant HSV-1 2, but this is unrelated to rivaroxaban safety

Hydroxyurea with Rivaroxaban

• No documented interaction exists between hydroxyurea and rivaroxaban
• Hydroxyurea is not listed as a CYP3A4 or P-gp modulator
• The FDA label for hydroxyurea 3 does not mention rivaroxaban or anticoagulant interactions
• Hydroxyurea's documented drug interactions are limited to:
  • Antiretroviral drugs (didanosine, stavudine) causing pancreatitis, hepatotoxicity, and peripheral neuropathy 3
  • Laboratory test interference 3

Critical Clinical Considerations

Bleeding Risk from Additive Effects

While no pharmacokinetic interaction exists, monitor closely for bleeding because:

• Hydroxyurea causes myelosuppression including thrombocytopenia 3
• Platelet depression (<100,000 cells/mm³) can occur with hydroxyurea 3
• Combined with rivaroxaban's anticoagulant effect, this creates additive bleeding risk through different mechanisms

Monitoring Recommendations

• Check complete blood count regularly to detect hydroxyurea-induced thrombocytopenia
• Assess renal function as both rivaroxaban and acyclovir are renally eliminated
• If platelet count drops significantly, consider holding rivaroxaban temporarily
• Watch for signs of bleeding (bruising, hematuria, melena, hemoptysis)

Renal Function Caveat

Both acyclovir and rivaroxaban require dose adjustment in renal impairment:

• If creatinine clearance <50 mL/min, rivaroxaban exposure increases significantly 1
• Acyclovir requires dose reduction in renal impairment
• Monitor renal function closely in patients on this combination

Common Pitfalls to Avoid

1. Don't assume all drug combinations with rivaroxaban are problematic - focus on CYP3A4/P-gp modulators
2. Don't ignore hematologic monitoring - hydroxyurea's bone marrow suppression is the real concern here, not a direct drug interaction
3. Don't overlook renal function - this is the most important parameter affecting both rivaroxaban and acyclovir safety